KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United…
Actionable offering helps enable earlier, more personalized breast cancer interventionsBOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025…
HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with…
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range…
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics…
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem…
KANAZAWA, Japan, Nov. 26, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in ACS…
TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a…
VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is…
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical…